NAD record shows Noom and Willow Health dropped challenged compounded-GLP-1 claims

BBB National Programs' National Advertising Division, known as NAD, closed two cases this year involving marketing for compounded GLP-1 products. In May 2026, NAD recommended that Noom modify or discontinue its "A Smaller Dose. A Smarter Start. Microdose GLP-1Rx Starts at $119" claim, finding it conveyed an unsupported message that a smaller dose by itself delivered a health benefit.^[1][2] Noom disagreed with that conclusion but voluntarily agreed to comply, and separately told NAD it was permanently dropping other claims about dosing, effectiveness and side effects, which NAD did not review on the merits as a result.^[1]

Separately, Willow Health Services, a Texas telehealth company, had ignored a December 2025 NAD decision that found its safety, efficacy and superiority claims for a compounded semaglutide product were unsubstantiated. Because Willow did not say whether it would comply, NAD referred the matter to the Federal Trade Commission, relevant state attorneys general, and the platforms carrying the ads.^[1][2] Willow later returned to NAD after talking with the FTC, and in July 2026 NAD confirmed the company had permanently discontinued all the challenged claims, which covered weight-loss support, comparability to FDA-approved semaglutide, and effectiveness without diet or exercise.^[1]

These cases sit inside a much larger campaign. Novo Nordisk has filed 130 federal lawsuits and five NAD challenges against compounders and telehealth sellers; Eli Lilly has filed dozens of federal lawsuits and at least five NAD challenges.^[1][2] Over the same period, the FDA has sent more than 100 warning letters over misbranded compounded GLP-1 claims, though that enforcement has stayed narrowly focused on issues like active ingredients and product performance.^[1][2] Lilly's tirzepatide franchise reached $40 billion in sales and Novo's semaglutide products generated $35 billion last year, according to Bloomberg Law.^[2]

NAD itself has no government authority. It is a voluntary, self-regulatory forum where the burden falls on the advertiser to show it has a reasonable basis for a claim; companies are not required to participate or follow its recommendations, but NAD can refer noncompliant cases to the FTC, state attorneys general or ad platforms, as happened with Willow.^[2]

Why it matters for patients

People considering a compounded GLP-1 product may see marketing language about "microdosing," comparability to brand-name drugs, or effectiveness without lifestyle changes. These two decisions show that at least some of those specific claims were found unsupported by an independent ad-review body and were pulled or changed as a result.^[1][2] That does not mean every compounded product on the market makes unsupported claims, and it does not settle questions about the safety or effectiveness of any specific compounded product, which NAD does not evaluate as a medical regulator. The FDA, not NAD, is the agency responsible for drug safety and approval, and its own enforcement in this area has so far focused on a narrower set of issues, according to lawyers quoted by Bloomberg Law.^[2] Patients weighing a compounded option are left to rely on FDA warning letters, NAD decisions, and their own research, since no single agency is systematically checking the accuracy of every marketing claim in this space.^[1][2]

What happens next

It is not yet known whether the FTC or any state attorney general will take further action against Willow Health Services following the referral.^[1] Litigation tied to the broader fight continues, including a federal antitrust suit filed by Strive Compounding Pharmacy against Lilly and Novo Nordisk over telehealth access, and an August 2026 Lilly lawsuit against six companies over alleged retatrutide sales.^[1] Whether other compounders and telehealth marketers will face new NAD challenges, and whether the FDA will broaden the scope of its warning letters beyond active-ingredient and performance claims, is also not yet known.^[1][2]